pharma · Narcolepsy and Idiopathic Hypersomnia · Narcolepsy Type 1 · CNTA
Centessa Pharmaceuticals
Centessa Pharmaceuticals plc
Centessa Pharmaceuticals patent portfolio — 7 USPTO pharmaceutical patents (A61K/A61P) with grant dates, status, and loss-of-exclusivity filters.
Company details
- Status
- Public
- HQ
- 1 Ashley Road, Cheshire, WA14 2DT, United Kingdom, GB
- Founded
- 2021
- Employees
- 142
- Programs
- 15
- Drugs
- 11
- Patents
- 7
Centessa Pharmaceuticals patents
7 pharmaceutical patents indexed for Centessa Pharmaceuticals. 0 expire within 24 months.
Centessa Pharmaceuticals has 7 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 0 expire within 24 months — use filters for patent-cliff planning.
Patent portfolio
-
US 12421310
CD47 binding agents
granted -
US 12415861
Anti C-MET antibodies
granted -
US 12365672
Compounds and their use for the treatment of alpha1-antitrypsin deficiency
granted -
US 12291507
Compounds and their use for the treatment of ALPHA1-antitrypsin deficiency
granted -
US 12286402
Compounds and their use for the treatment of alpha1-antitrypsin deficiency
granted -
US 12227580
Antigen binding molecules that bind LIGHT
granted -
US 12221422
Compounds and their use for the treatment of alpha1-antitrypsin deficiency
granted
Frequently asked questions
How many patents does Centessa Pharmaceuticals have?
7 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do Centessa Pharmaceuticals patents expire?
0 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.